3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Leukemia, Myeloid, Acute
10
Myelodysplastic Syndromes
4
Mycoses
4
Hematologic Neoplasms
3
Neoplasms
2
Leukemia
2
Brain Neoplasms
2
Triple Negative Breast Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neutropenia
1
Neoplasm, Residual
1
Myelodysplastic-Myeloproliferative Diseases
1
Leukemia, Myeloid
1
Invasive Fungal Infections
1
Glioma
1
Glioblastoma
1
Genetic Predisposition to Disease
1
Candidiasis
1
Bronchiolitis Obliterans Syndrome
1
Breast Neoplasms
1
Bone Marrow Neoplasms
1
Bone Marrow Failure Disorders
1
Aspergillosis
1
Anemia, Aplastic
1
Interventions
Trastuzumab
594
Paclitaxel
561
Cyclophosphamide
545
Docetaxel
478
Capecitabine
387
Letrozole
350
Fulvestrant
310
Doxorubicin
285
Carboplatin
277
Tamoxifen
257
Anastrozole
219
exemestane
211
Epirubicin
210
Radiotherapy
197
Bevacizumab
189
pertuzumab
175
Gemcitabine
163
Vinorelbine
162
pembrolizumab
161
Lapatinib
161
palbociclib
152
Exercise
132
Fluorouracil
118
Albumin-Bound Paclitaxel
116
eribulin
108
Magnetic Resonance Spectroscopy
108
130-nm albumin-bound paclitaxel
107
Everolimus
103
Taxes
96
Cisplatin
92
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Breast Neoplasms
×
posaconazole
×
Clear all
NCT06802757
2026-02-25
PRISM-TNBC
Shandong Cancer Hospital and Institute
Phase 2
Recruiting
72 enrolled